Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

Anitocabtagene autoleucel yielded an overall response rate of 97% in relapsed/refractory multiple myeloma.

Anito-Cel Drives Durable Responses in R/R Multiple Myeloma

The IRAKLIA study examined the use of an innovative on-body injector for isatuximab administration in multiple myeloma.

IRAKLIA Data Support Subcutaneous Isatuximab as a SOC Administration Approach in Myeloma

Dasatinib added to induction and consolidation, then continued as maintenance, did not improve survival in core-binding factor AML.

Addition of Dasatinib to Induction/Consolidation Fails to Boost Survival in Core-Binding Factor AML

Talquetamab plus cetrelimab showed safety and efficacy in R/R multiple myeloma, including in patients previously treated with bispecific antibodies.

Talquetamab/Cetrelimab Leads to Deep, Durable Responses in R/R Multiple Myeloma 

News

OncClub

All Oncology News

Media

Insights

MedNews Week

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

CME/CE

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Webinars

Partners

Publications

Resources

Consensus Viewpoints

OncLive App

Interactive Tools

Biomarker Consortium

Subscribe

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Articles

 
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource 

. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com


Gina Mauro is your lead editorial contact for 

. She joined the company in 2015 and has held various positions on 

; she is also the on-air correspondent for 

. Prior to joining MJH Life Sciences, she worked at Gannett as a full-time reporter with the Asbury Park Press. Email: gmauro@onclive.com 

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

The OncLive Insider app is live!

CME Opportunities

Specialty

OncLive News Network

 is a dynamic video series from Med News Week and OncLive, bringing you rapid-fire insights from top oncology experts at the 2025 ASCO Annual Meeting. 

On the Clock With MedNews Week: ASCO 2025

Videos

MedNews Week host Yan Leyfman, MD, speaks with 4 key opinion leaders at ASCO 2025 about the top data highlights of the day.

ASCO 2025: Top Data Highlights from 5/31

MedNews Week hosts speak with 5 key opinion leaders at ASCO 2025 about the top data highlights of the day.

ASCO 2025: Top Data Highlights from 6/1

MedNews Week hosts speak with 8 key opinion leaders at ASCO 2025 about the top data highlights of the day.

ASCO 2025: Top Data Highlights from 6/2

MedNews Week host Yan Leyfman, MD, speaks with 2 key opinion leaders at ASCO 2025 about the top data highlights of the day.

ASCO 2025: Top Data Highlights from 6/3

On the Clock With MedNews Week: ASCO 2025

Latest Conference Coverage